Multiple organ lesion in hemochromatosis
https://doi.org/10.51523/2708-6011.2022-19-1-18
Abstract
Abstract
Primary hemochromatosis refers to a congenital autosomal recessive disease associated with a mutation of the homeostatic iron regulator (HFE gene), whose pathogenetic mechanism is increased iron absorption in the intestines, which leads to excessive accumulation of iron in organs and tissues, mainly in the liver, pancreas, heart, pituitary gland, testicles. The consequence of the disease is the development of fibrosis and insufficiency of these organs. Genotyping of HFE gene mutations is the main method of hemochromatosis verification. The presence of the C282Y/C282Y genotype in combination with iron overload manifestations is a diagnostic criterion of the disease. The basic treatment of patients with hemochromatosis is phlebotomy, which can be combined with the prescription of iron chelators, symptomatic therapy.
A clinical case of primary hemochromatosis in a 48-year-old man is of interest due to long-term persistence of certain symptomatic manifestations of hemochromatosis and verification of the disease only after decompensation of a cardiovascular pathology and magnetic resonance imaging (MRI) of the thoracic cavity. After obtaining the final diagnosis and treatment, the patient showed positive dynamics of clinical symptoms, laboratory and instrumental data.
About the Authors
E. G. Malaeva
Gomel State Medical University
Belarus
Belarus
Ekaterina G. Malaeva, PhD (Med), Associate Professor, Head of Department of Internal Diseases No.1 with the courses of Endocrinology and Hematology
Gomel
E. I. Adamenko
Belarusian Medical Academy of Postgraduate Education
Belarus
Belarus
Elena I. Adamenko, PhD (Med), Associate Professor, Associate Professor at the Department of Gastroenterology and Nutritionology
Minsk
O. M. Zharskaya
Belarusian Medical Academy of Postgraduate Education
Belarus
Belarus
Olga M. Zharskaya, PhD (Med), Associate Professor, Associate Professor at the Department of Gastroenterology and Nutritionology
Minsk
A. A. Gavrusev
Belarusian State Medical University
Belarus
Belarus
Аndrey А. Gavrusev, PhD (Med), Associate Professor, Associate Professor at the Department of Urology
Minsk
Zh. M. Kozich
Republican Scientific and Practical Center for Radiation Medicine and Human Ecology
Belarus
Belarus
Zhanna M. Kozich, PhD (Med), hematologist at the Hematology Department for Adults
Gomel
References
1. Katsarou MS, Papasavva M, Latsi R, Drakoulis N. Hemochromatosis: Hereditary hemochromatosis and HFE gene. Vitam Horm. 2019;110:201-222. https://doi.org/10.1016/bs.vh.2019.01.010
2. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010;53(1):3-22. https://doi.org/10.1016/j.jhep.2010.03.001
3. Brissot P, Pietrangelo A, Adams PC, de Graaff B, McLaren CE, Loréal O. Haemochromatosis. Nat Rev Dis Primers. 2018;4:18016. https://doi.org/10.1038/nrdp.2018.16
4. Zoller H, Henninger B. Pathogenesis, Diagnosis and Treatment of Hemochromatosis. Dig Dis. 2016;34(4):364-73. https://doi.org/10.1159/000444549
5. The clinical protocol “Diagnosis and treatment of patients with diseases of the digestive system” was approved by the Decree of the Ministry of Health of the Republic of Belarus No. 54 on 01.06.2017. [date of access 2022 December 23]. Available from: http://minzdrav.gov.by/ru/dlya-spetsialistov/standarty-obsledovaniya-i-lecheniya/gastroenterologiya.php (in Russ.).
6. Klaritskaya IL, Maksimova EV. Clinical practical recommendations for the management of patients with hemochromatosis. Crimean Journal of Internal Diseases. 2012;19 (2):41-46. (in Russ.). [date of access 2022 December 23]. Available from: http://crimtj.ru/Journal.files/19-2012-2/FM-Maksimova-Hemochromatosis.pdf (in Russ.).
7. Kowdley KV, Brown KE, Ahn J, Sundaram V. ACG Clinical Guideline: Hereditary Hemochromatosis. Am J Gastroenterol. 2019;114(8):1202-1218. https://doi.org/10.14309/ajg.0000000000000315
8. Salgia RJ, Brown K. Diagnosis and management of hereditary hemochromatosis. Clin Liver Dis. 2015;19(1):187-198. https://doi.org/10.1016/j.cld.2014.09.011
9. Voloshinа NB, Osipenko MF, Litvinova NV, Voloshin AN. Hemochromatosis modern condition of the problem. Ter Arkh. 2018;90(3):107-112. https://doi.org/10.26442/terarkh2018903107-112
10. Golfeyz S, Lewis S, Weisberg IS. Hemochromatosis: pathophysiology, evaluation, and management of hepatic iron overload with a focus on MRI. Expert Rev Gastroenterol Hepatol. 2018;12(8):767-778. https://doi.org/10.1080/17474124.2018.1496016
11. Pelusi C, Gasparini DI, Bianchi N, Pasquali R. Endocrine dysfunction in hereditary hemochromatosis. J Endocrinol Invest. 2016;39(8):837-47. https://doi.org/10.1007/s40618-016-0451-7
12. Kawabata H. The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis. Int J Hematol. 2018;107(1):31-43. https://doi.org/10.1007/s12185-017-2365-3
13. Palmer WC, Vishnu P, Sanchez W, Aqel B, Riegert-Johnson D, et al. Diagnosis and management of genetic iron overload disorders. J Gen Intern Med. 2018;33(12):2230-2236. https://doi.org/10.1007/s11606-018-4669-2
14. Skvortsov BB, Gorbach AN. Liver lesions in hemochromatosis: clinical manifestations and diagnosis. Effective pharmacotherapy. 2020;16(1):74-78. (in Russ.). https://doi.org/10.33978/2307-3586-2020-16-174-78
15. Solovyova AV, Kodyakova OV, Nikitina IN, Fomenko NP, Rakita DR. A clinical case of hereditary hemochromatosis. Kazan med j. 2018;99(6):998-1003. (in Russ.). https://doi.org/https://doi.org/10.17816/KMJ2018-998
Review
For citations:
Malaeva E.G., Adamenko E.I., Zharskaya O.M., Gavrusev A.A., Kozich Zh.M. Multiple organ lesion in hemochromatosis. Health and Ecology Issues. 2022;19(1):139-144. (In Russ.) https://doi.org/10.51523/2708-6011.2022-19-1-18
Views: 557
Email this article 